Oruka Therapeutics, Inc. Debt Securities, Available-for-sale, Noncurrent
Oruka Therapeutics, Inc. (ORKA) had Debt Securities, Available-for-sale, Noncurrent of $2.35 million as of 2016-12-31, per its 10-K filed 2018-03-22.
Discontinued › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2018-03-22
- 2016-12-31: Debt Securities, Available-for-sale, Noncurrent $2.35M.
- 2016-09-30: Debt Securities, Available-for-sale, Noncurrent $3.97M.
- 2016-06-30: Debt Securities, Available-for-sale, Noncurrent $5.01M.
- 2016-03-31: Debt Securities, Available-for-sale, Noncurrent $5.31M.
| Period end | Debt Securities, Available-for-sale, Noncurrent |
|---|---|
| 2016-12-31 | $2.35M 10-K · filed 2018-03-22 |
| 2016-09-30 | $3.97M 10-Q · filed 2016-11-14 |
| 2016-06-30 | $5.01M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $5.31M 10-Q · filed 2016-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Veradermics, Inc (MANE) | United States | $4.839B |